Introduction About CELEBREX 200MG CAPSULE

CELEBREX 200MG CAPSULE contains Celecoxib which belongs to group of medicines called Non-steroidal anti-inflammatory drugs. CELEBREX 200MG CAPSULE is used in adults to manage osteoarthritis (degenerative joint disease), rheumatoid arthritis (inflammatory disease of joints), ankylosing spondylitis (chronic back pain), acute pain and primary dysmenorrhea (menstrual cramps).

CELEBREX 200MG CAPSULE is also used to manage juvenile rheumatoid arthritis (in children aged 2 years and above).

CELEBREX 200MG CAPSULE is not recommended for use in patients allergic to Celecoxib, sulfonamides, aspirin and/or other NSAIDs. It is also not recommended for use in patients with/had a history of an ulcer in stomach/intestines, bleeding in stomach/intestines, blood circulation problems (such as peripheral arterial disease), red itchy welts, inflammatory disease of the intestines (such as ulcerative colitis/Crohn’s disease).

The medicine is also not indicted for use in patients suffering from lung problems (such as asthma), heart diseases (such as heart failure, recent heart attack, heart block), severe liver disease (such as advanced hepatic insufficiency) and/or kidney disease (such as advanced renal insufficiency).

Before taking CELEBREX 200MG CAPSULE, inform your doctor if you have diabetes, raised blood pressure, increased cholesterol, signs of fluid retention (such as swollen ankles and feet) and/or hyperkalemia (increased potassium level in blood).

CELEBREX 200MG CAPSULE is not recommended for use in pregnant and breast-feeding women.

CELEBREX 200MG CAPSULE should be used with caution in children and adolescents (aged 2 to 17 years) to manage only juvenile rheumatoid arthritis and is advised to be used with caution in elderly patients (aged 65 years/above) after consulting the doctor.

The most common side effects of taking CELEBREX 200MG CAPSULE are high blood pressure, shortness of breath, sore throat, cough, headache, nausea and dizziness. Consult your doctor if any of these symptoms worsen.

The generic name of CELEBREX 200MG CAPSULE is Celecoxib which is also used for other uses.Show By In

Ce veterinary prescription

CELEBREX 200MG CAPSULE is a prescription medicine. You must present the name of the drug you are taking CELEBREX 200MG CAPSULE to the doctor. medicine. You need not let lies keep you from doing so.

How to use CELEBREX 200MG CAPSULE

Take this medicine in the dose and duration as advised by your doctor.

Do not take CELEBREX 200MG CAPSULE if you are hypersensitive to it. Consult your doctor if you notice the 3023 active ingredient (Celecoxib) or other Celecoxib (Celebrexib) or other NSAIDs (such as ASA) including Ibosset®

Talk to your doctor before taking CELEBREX 200MG CAPSULE if you:

• You are taking Celecoxib for osteoarthritis or rheumatoid arthritis to manage juvenile rheumatoid arthritis and ankylosing spondylitis.
• You have osteoarthritis and rheumatoid arthritis? Both. (Celebrex®)
• Have ankylosing spondylitis? You recently had an onset juvenile rheumatoid arthritis? Both?
• You have an onset of rheumatoid arthritis?

Before taking CELEBREX 200MG CAPSULE, inform your doctor if you:

• You have asthma? Allergic to CELEBREX 200MG CAPSULE.
• You have severe liver disease? Circling disease (such as advanced hepatic insufficiency) with liver problems (such as Cirrhoea with advanced liver insufficiency).
• You are trying to have a child with bone pain? CELEBREX 200MG CAPSULE must be used with caution in the elderly after consulting your doctor.

The world's largest arthritis joint manufacturer announced on Monday that it would pay $5.8 billion to settle lawsuits brought by people who were injured after taking a Celebrex-approved treatment for pain and inflammation, which is used to treat arthritis.

The settlement is expected to be announced on Friday, when the FDA will begin its final review of Celebrex, a COX-2 inhibitor.

The arthritis joint plaintiffs allege that Celebrex caused their pain and inflammation, and that the Celebrex-treated arthritis patients were taking the drug for years.

The U. S. District Court in New York issued a judgment in February that found that the Celebrex-treated arthritis patients had failed to take adequate amounts of pain relieving drugs. The judge also found that the Celebrex-treated arthritis patients also had not been making enough of the drug’s active ingredient, the active ingredient in Celebrex.

The Celebrex-treated arthritis patients’ injuries and claims were based on the scientific evidence presented by the doctors who reviewed the clinical trials. The FDA will issue its final decision on Monday.

“These cases demonstrate the significant impact on these patients’ quality of life and the need for an appropriately prescribed Celebrex-approved treatment,” said John L. Lechleiter, MD, of New York University, and former head of the arthritis and other medical research division at Pfizer.

“Our patients deserve the full range of care they deserve and should not have to suffer the consequences that were caused by taking this drug.”

In the settlement, the Celebrex-treated arthritis patients were given a “comprehensive, individualized risk assessment” that detailed how they were taking the drug, how often they took it, and how long the drug was in use.

The judge determined that “the full range of potential harm is unknown” and “did not find evidence that the patients were taking adequate doses of the drug”.

The judge also found that the Celebrex-treated arthritis patients had not made adequate amounts of the drug’s active ingredient, the active ingredient in Celebrex, and that the Celebrex-treated arthritis patients had not been taking adequate amounts of the drug’s other active ingredients, such as the pain reliever.

“The Celebrex-treated arthritis patients had not demonstrated a significant amount of the active ingredient in the Celebrex-treated arthritis patients’ medications,” the judge wrote.

The judge ordered the manufacturers to produce proof of the Celebrex-treated arthritis patients’ injury and side effects, and to produce a “clear and convincing” medical history.

The FDA said that it has received more than $2 million in claims and that the company has filed more than 1,500 pharmaceutical patent infringement suits and several dozen patent infringement lawsuits.

Ajanta Pharma & Upjohn, Inc.

In one of the most recent studies, the results of a study on Celebrex-treated arthritis patients have been inconsistent. The study showed that the Celebrex-treated arthritis patients had an increased risk of serious adverse events, including a decreased incidence of bleeding, heart attack, stroke, gastrointestinal bleeding, and kidney damage.

The FDA’s analysis of the study revealed that Celebrex caused the pain and inflammation seen in patients, and that the Celebrex-treated arthritis patients had “a decreased incidence of serious adverse events.”

According to the FDA, the study was “not designed to show that Celebrex caused a serious adverse event in patients taking the medication.”

In the United States, the drug is sold under brand names such as Celebrex, and the drug’s generic versions include the generic drug. However, the FDA has not approved Celebrex for use in the United States.

In other cases, the Celebrex-treated arthritis patients have not been diagnosed with arthritis, and the Celebrex-treated arthritis patients have not been prescribed a specific arthritis pain reliever, such as ibuprofen, pain medication or NSAIDs.

Product description

Product name:Celebrex

Company name:

DIN:02245130

Status:Marketed

Status date:2017-11-30

Active ingredient(s)	Strength
celecoxib	100 MG

Resources

Click on a resource to visit a page with more information. You may be taken away from this page to a different Government of Canada website.

For consumers

Resource	Description
The Product Monograph is a scientific document that describes the properties, claims, indications and conditions of use of the product and contains any other information that may be required for optimal, safe and effective use. The Product Monograph includes three sections: Part I: Health Professional Information; Part II: Scientific Information; and Patient Medication Information
Side effects are troublesome symptoms or feelings that you may not expect that show up when you are taking a medicine. All suspected side effects should be reported, especially those that are: Unexpected, regardless of their severity, i.e., not consistent with product information or labelling; or Serious, whether expected or not, i.e., that requires being admitted to the hospital, lengthened hospital stay, causes a birth defect, disability, is life-threatening or results in death; Reactions to recently marketed health products (on the market for less than five years), regardless of their nature or severity.

For health care professionals

Section C.01.020.1 of the Food and Drug Regulations and section 62 of the Medical Devices Regulations, require hospitals to report to Health Canada all serious adverse drug reactions (ADRs) and medical device incidents (MDIs) within 30 days of being documented within the hospital. This regulatory requirement only applies to hospitals.

For researchers

After Health Canada completes the regulatory review process for a product, the clinical information included in a submission is made publicly available for non-commercial purposes.

All resources

Treatmentfor Celebrex (Celecoxib) was introduced in February of 1999 and remains an effective treatment for COX-2 inhibitors in the United States. Although it was approved by the Food and Drug Administration (FDA) in January of 1999, it was discontinued in March of 2001 due to the severe side effects of gastrointestinal bleeding. Celebrex is indicated in the treatment of postoperative pain. As an adjunct to pain management, it is useful in patients with acute myocardial infarction, stroke, or coronary artery bypass graft (CABG). It also can be used as an adjunct to other therapies to reduce pain. Celebrex is also indicated to lower levels of certain heart medications in patients who have experienced COX-2 inhibitor-associated heart attack (CABG) at the time of their initial administration of Celebrex. This is done to improve patient comfort, reduce the likelihood of the occurrence of severe cardiovascular events, and lower the need for coronary bypass surgery.

Mechanism of Actionof Celebrexis shown in. It has been shown that Celebrex has a weak affinity for the COX-2 enzymes in the GI tract. Celebrex has been shown to inhibit the COX-2 enzyme with an IC50 value of approximately 1.3 mg/100 mL. This inhibition is not due to the inhibition of the enzyme itself or the inhibition of a sub-inhibitory concentration of the drug.

Advantagesof Celebrex include:

• It is a selective inhibitor of cyclooxygenase (COX-2).
• It is well tolerated, as well as effective in treating COX-2 inhibitor-associated heart attack.

Side Effects

• Nausea and vomiting.
• Headache.
• Dizziness.
• Decreased appetite.
• Rash.

of Celebrex is shown in. Celebrex has been shown to reduce the production of prostaglandins by inhibiting the COX-2 enzyme.

Safetyof Celebrex is not associated with the use of aspirin. It is generally well tolerated and has been shown to be safe for patients and caregivers who are using Celebrex. However, there is some evidence that Celebrex can cause a serious allergic reaction. The mechanism of this reaction is unknown but probably involves a combination of an increased synthesis of prostaglandins, with the consequent increase in prostaglandin formation. Celebrex is contraindicated in patients who are using other drugs that can cause an allergic reaction.

• Drowsiness.

Celebrex, Celecoxib, and Ibuprofen

Celebrex and Celecoxib (brand names like Celebrex, Celebrex XR, and Celebrex Ibuprofen) are a combination drug used to treat inflammation of the lower back. These medications have analgesic, anti-inflammatory, and anti-platelet actions. Ibuprofen works by inhibiting prostaglandin synthesis in the stomach and intestine. It is used as a first line painkiller or anti-inflammatory in doses of 50 to 200 mg every 12 hours for acute pain or for up to 4 weeks to prevent ulcers and bleeding in conditions such as ulcerative colitis and perforation. Celecoxib is used in doses of 400 to 800 mg every 12 hours for acute pain, up to 4 weeks, to reduce pain and swelling in patients with post-operative pain and/or arthritis. Celebrex and Celecoxib are used to treat menstrual cramps and other related conditions, including arthritis, that have been accompanied by an increased risk of osteoarthritis. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that is used for the treatment of pain in osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, juvenile rheumatoid arthritis, and ankylosing spondylitis.